What is Singulex?
Founded in 1997 and headquartered in Alameda, California, Singulex specializes in the development and commercialization of single-molecule counting technology. This platform provides unprecedented sensitivity in clinical diagnostics, enabling the detection of biomarkers at concentrations previously invisible to standard laboratory equipment. By bridging the gap between scientific discovery and routine clinical application, Singulex has established a robust footprint in the life sciences sector, focusing on high-precision diagnostics that improve patient outcomes and streamline clinical decision-making processes.
How much funding has Singulex raised?
Singulex has raised a total of $151.8M across 6 funding rounds:
Series C
$8.4M
Series D
$19M
Series E
$19M
Series F
$15.3M
Debt
$40M
Private Equity
$50M
Series C (2006): $8.4M with participation from BioProfile Holding Company, Fisk Ventures, and Prolog Capital
Series D (2009): $19M led by Jafco ventures and OrbiMed
Series E (2009): $19M supported by JAFCO Japan, Fisk Ventures, and OrbiMed
Series F (2012): $15.3M, investors not publicly disclosed
Debt (2013): $40M backed by Silicon Valley Bank and Oxford Finance
Private Equity (2016): $50M with participation from Grifols
Key Investors in Singulex
Grifols
A global healthcare leader based in Spain, Grifols specializes in plasma-derived medicines and diagnostic solutions, maintaining a long-term commitment to innovation and patient well-being.
OrbiMed
A specialized investment firm focused exclusively on the healthcare sector, OrbiMed provides deep expertise across biopharmaceuticals, medical devices, and diagnostic platforms.
Oxford Finance
A specialty finance firm that provides flexible capital solutions tailored specifically to the unique needs of healthcare and life sciences companies worldwide.
What's next for Singulex?
Following its major strategic investment, Singulex is well-positioned to accelerate the commercial deployment of its diagnostic platforms. The company's trajectory suggests a shift toward broader market penetration and the integration of its technology into global healthcare systems. By leveraging its established partnerships with industry leaders, Singulex is expected to focus on scaling its operational capacity and expanding its diagnostic menu, ensuring that its high-sensitivity solutions become the standard for early disease detection and therapeutic monitoring in the enterprise healthcare market.
See full Singulex company page
